The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Pomalidomide plus low-dose dexamethasone (POM plus LoDEX) versus high-dose dexamethasone (HiDEX) for relapsed or refractory multiple myeloma (RRMM): Overall survival (OS) results of MM-003 after adjustment for crossover.
Gareth J Morgan
Honoraria - Celgene
Research Funding - Celgene
Jesus San Miguel
Consultant or Advisory Role - Bristol-Myers Squibb; Celgene; Janssen; Millennium; MSD; Novartis; Onyx
Sujith Dhanasiri
Employment or Leadership Position - Celgene
Dawn Lee
Consultant or Advisory Role - Celgene
Antonio Palumbo
Consultant or Advisory Role - Amgen; Bristol-Myers Squibb; Celgene; Janssen; Millennium; Onyx
Honoraria - Amgen; Bristol-Myers Squibb; Celgene; Janssen; Millennium; Onyx
Thierry Facon
Consultant or Advisory Role - Celgene
Mohamed H. Zaki
Employment or Leadership Position - Celgene
Xin Yu
Employment or Leadership Position - Celgene
Lars Axel Sternas
Employment or Leadership Position - Celgene
Christian Jacques
Employment or Leadership Position - Celgene
Katja C. Weisel
Consultant or Advisory Role - Celgene; Janssen; Onyx
Honoraria - Celgene; Janssen; Onyx
Fritz Offner
No relevant relationships to disclose
Meletios A. Dimopoulos
Honoraria - Celgene; Northwest Biotherapeutics